FOXA1 is an independent prognostic marker for ER-positive breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 3, 2012, Pages 881-890

  Mehta, Rutika J ^a   Jain, Rohit K ^a   Leung, Samuel ^c   Choo, Jennifer ^c   Nielsen, Torsten ^c   Huntsman, David ^c   Nakshatri, Harikrishna ^a   Badve, Sunil ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; ER; FOXA1 expression; PR; Prognostic significance; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FOXA1 GENE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 85028112875     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1482-6     Document Type: Article

References (35)

1. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
2. JS Carroll XS Liu AS Brodsky W Li CA Meyer AJ Szary J Eeckhoute W Shao EV Hestermann TR Geistlinger EA Fox PA Silver M Brown 2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FOXA1 Cell 122 1 33 43 16009131 10.1016/j.cell.2005.05.008 1:CAS:528:DC%2BD2MXmsFeitbg%3D
3. J Laganiere G Deblois C Lefebvre AR Bataille F Robert V Giguere 2005 From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response Proc Natl Acad Sci 102 33 11651 11656 16087863 10.1073/pnas.0505575102 1:CAS:528: DC%2BD2MXpsFGgtro%3D
4. RH Costa DR Grayson JE Darnell Jr 1989 Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes Mol Cell Biol 9 4 1415 1425 2786140 1:CAS:528: DyaL1MXhvVOitbg%3D
5. A Hurtado KA Holmes CS Ross-Innes D Schmidt JS Carroll 2011 FOXA1 is a key determinant of estrogen receptor function and endocrine response Nat Genet 43 1 27 33 21151129 10.1038/ng.730 1:CAS:528:DC%2BC3cXhsFGgtrnK
6. KL Clark ED Halay E Lai SK Burley 1993 Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5 Nature 364 6436 412 420 8332212 10.1038/364412a0 1:CAS:528:DyaK3sXlsFehtLY%3D
7. JS Carroll M Brown 2006 Estrogen receptor target gene: an evolving concept Mol Endocrinol 20 8 1707 1714 16396959 10.1210/me.2005-0334 1:CAS:528:DC%2BD28XnvFajsrg%3D
8. H Kouros-Mehr EM Slorach MD Sternlicht Z Werb 2006 GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland Cell 127 5 1041 1055 17129787 10.1016/j.cell.2006.09.048 1:CAS:528:DC%2BD28XhtlWktrzP
9. ML Asselin-Labat KD Sutherland H Barker R Thomas M Shackleton NC Forrest L Hartley L Robb FG Grosveld J van der Wees GJ Lindeman JE Visvader 2007 GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation Nat Cell Biol 9 2 201 209 17187062 10.1038/ncb1530 1:CAS:528:DC%2BD2sXhtFGlsbo%3D
10. FO Ademuyiwa MA Thorat RK Jain H Nakshatri S Badve 2010 Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores Mod Pathol 23 2 270 275 19946260 10.1038/modpathol.2009.172 1:CAS:528:DC%2BC3cXhsVyjtb4%3D
11. I Wolf S Bose EA Williamson CW Miller BY Karlan HP Koeffler 2007 FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer Int J Cancer 120 5 1013 1022 17163418 10.1002/ijc.22389 1:CAS:528:DC%2BD2sXhsVWhsrs%3D
12. EA Williamson I Wolf J O'Kelly S Bose S Tanosaki HP Koeffler 2006 BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1) Oncogene 25 9 1391 1399 16331276 10.1038/sj.onc.1209170 1:CAS:528:DC%2BD28XhvFaisrc%3D
13. M West C Blanchette H Dressman E Huang S Ishida R Spang H Zuzan JA Olson Jr JR Marks JR Nevins 2001 Predicting the clinical status of human breast cancer by using gene expression profiles Proc Natl Acad Sci 98 20 11462 11467 11562467 10.1073/pnas.201162998 1:CAS:528:DC%2BD3MXnt1yqu7w%3D
14. MA Thorat C Marchio A Morimiya K Savage H Nakshatri JS Reis-Filho S Badve 2008 Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis J Clin Pathol 61 3 327 332 18037662 10.1136/jcp.2007.052431 1:STN:280:DC%2BD1c7ksVamtQ%3D%3D
15. S Badve D Turbin MA Thorat A Morimiya TO Nielsen CM Perou S Dunn DG Huntsman H Nakshatri 2007 FOXA1 expression in breast cancer-correlation with luminal subtype A and survival Clin Cancer Res 13 15 Pt 1 4415 4421 17671124 10.1158/1078-0432.CCR-07-0122 1:CAS:528:DC%2BD2sXotlGqt78%3D
16. H Nakshatri S Badve 2007 FOXA1 as a therapeutic target for breast cancer Expert Opin Ther Targets 11 4 507 514 17373880 10.1517/14728222.11.4.507 1:CAS:528:DC%2BD2sXjt1Sru7Y%3D
17. A Albergaria J Paredes B Sousa F Milanezi V Carneiro J Bastos S Costa D Vieira N Lopes EW Lam N Lunet F Schmitt 2009 Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours Breast Cancer Res 11 3 R40 19549328 10.1186/bcr2327
18. HO Habashy DG Powe EA Rakha G Ball C Paish J Gee RI Nicholson IO Ellis 2008 Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance Eur J Cancer 44 11 1541 1551 18538561 10.1016/j.ejca.2008.04.020 1:CAS:528:DC%2BD1cXotlClsb0%3D
19. SK Chia CH Speers CJ Bryce MM Hayes IA Olivotto 2004 Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies J Clin Oncol 22 9 1630 1637 15117985 10.1200/JCO.2004.09.070
20. C Lohrisch J Jackson A Jones D Mates IA Olivotto 2000 Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer J Clin Oncol 18 15 2828 2835 10920130 1:STN:280:DC%2BD3cvitFemtw%3D%3D
21. J Kononen L Bubendorf A Kallioniemi M Barlund P Schraml S Leighton J Torhorst MJ Mihatsch G Sauter OP Kallioniemi 1998 Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 7 844 847 9662379 10.1038/nm0798-844 1:CAS:528:DyaK1cXktlKntr8%3D
22. RL Parker DG Huntsman DW Lesack JB Cupples DR Grant M Akbari CB Gilks 2002 Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray Am J Clin Pathol 117 5 723 728 12090420 10.1309/PEF8-GL6F-YWMC-AG56
23. MC Cheang SK Chia D Voduc D Gao S Leung J Snider M Watson S Davies PS Bernard JS Parker CM Perou MJ Ellis TO Nielsen 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 10 736 750 19436038 10.1093/jnci/djp082 1:CAS:528:DC%2BD1MXmtlyit74%3D
24. MC Cheang DO Treaba CH Speers IA Olivotto CD Bajdik SK Chia LC Goldstein KA Gelmon D Huntsman CB Gilks TO Nielsen AM Gown 2006 Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival J Clin Oncol 24 36 5637 5644 17116944 10.1200/JCO.2005.05.4155 1:CAS:528:DC%2BD2sXhtVChsrs%3D
25. S Chia B Norris C Speers M Cheang B Gilks AM Gown D Huntsman IA Olivotto TO Nielsen K Gelmon 2008 Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 35 5697 5704 19001334 10.1200/JCO.2007.15.8659 1:CAS:528:DC%2BD1MXotFemsw%3D%3D
26. SJ Crabb CD Bajdik S Leung CH Speers H Kennecke DG Huntsman KA Gelmon 2008 Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study Breast Cancer Res 10 1 R6 18194560 10.1186/bcr1847
27. D Voduc M Cheang T Nielsen 2008 GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value Cancer Epidemiol Biomarkers Prev 17 2 365 373 18268121 10.1158/1055-9965.EPI- 06-1090 1:CAS:528:DC%2BD1cXhslaru70%3D
28. MP Wong M Cheang E Yorida A Coldman CB Gilks D Huntsman K Berean 2008 Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients Pathology 40 6 611 616 18752129 10.1080/00313020802320614 1:CAS:528:DC%2BD1cXhtVGnsbzM
29. J Eeckhoute M Lupien CA Meyer MP Verzi RA Shivdasani XS Liu M Brown 2009 Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers Genome Res 19 3 372 380 19129543 10.1101/gr.084582.108 1:CAS:528:DC%2BD1MXjt12ktbk%3D
30. S Badve H Nakshatri 2009 Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications J Clin Pathol 62 1 6 12 18794199 10.1136/jcp.2008.059899 1:CAS:528:DC%2BD1MXhslyksLY%3D
31. AS Doane M Danso P Lal M Donaton L Zhang C Hudis WL Gerald 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 28 3994 4008 16491124 10.1038/sj.onc.1209415 1:CAS:528:DC%2BD28Xmtlahs7o%3D
32. N Yamaguchi E Ito S Azuma R Honma Y Yanagisawa A Nishikawa M Kawamura J Imai K Tatsuta J Inoue K Semba S Watanabe 2008 FOXA1 as a lineage-specific oncogene in luminal type breast cancer Biochem Biophys Res Commun 365 4 711 717 18039470 10.1016/j.bbrc.2007.11.064 1:CAS:528:DC%2BD2sXhsVCks7jI
33. HL Chua P Bhat-Nakshatri SE Clare A Morimiya S Badve H Nakshatri 2007 NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 Oncogene 26 5 711 724 16862183 10.1038/sj.onc.1209808 1:CAS:528: DC%2BD2sXhtFGmurs%3D
34. DL Hershman LH Kushi T Shao D Buono A Kershenbaum WY Tsai L Fehrenbacher S Lin Gomez S Miles AI Neugut 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients J Clin Oncol 28 27 4120 4128 20585090 10.1200/JCO.2009.25.9655
35. L Harris H Fritsche R Mennel L Norton P Ravdin S Taube MR Somerfield DF Hayes RC Bast Jr 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 33 5287 5312 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK